Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Key claim: A Phase IIa open-label randomized multicenter trial is evaluating flonoltinib maleate tablets at multiple dose levels for safety, efficacy, and pharmacokinetics in polycythemia vera patients resistant or intolerant to hydroxyurea or interferon.
Abstract
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon。The study divided into two stages: dose exploration stage: three dose groups are tentatively set, with three subjects in each group, totaling nine subjects in each group; Dose extension stage: Based on the safety, efficacy, and pharmacokinetic results of the comprehensive dose exploration stage, 2-3 dose groups are planned to be selected for dose extension trials.
Why this matters
Flonoltinib maleate joins a growing pipeline of novel JAK inhibitors being evaluated specifically in PV patients who have failed standard cytoreduction (hydroxyurea or interferon), a population with limited approved options beyond ruxolitinib. The Phase IIa multi-dose design will help define the therapeutic window for this agent in the resistant/intolerant PV subpopulation, contributing to the broader question of whether next-generation JAK inhibitors can improve on ruxolitinib’s efficacy or tolerability profile in PV.